Ascentage Pharma Group International - Unsponsored ADR AAPG

14.86 (0.37) (2.43%) as of 25 Sep
Market cap
$1.4B
P/E
—

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Older periods Dec '24 Jun '25 Dec '25 Jun '26
Net Income

+2 more quarters

(54.15) 0.00 (176.75) 0.00
Depreciation & Amortization
11.24 — 10.84 —
Other operating activities
12.45 — 18.53 —
Operating Cash Flow
(15.26) — (167.90) (85.66)
Capital expenditures
(3.33) — (3.94) (1.75)
Net Aquisitions
0.00 — 0.00 —
Long-Term Investments Change (Net)
— — — (0.44)
Other investing activities
(44.08) — (138.49) 139.32
Investing cash flow
(49.60) — (143.01) 137.13
Repayment/Issuance of Debt (Net)
0.00 — 0.00 15.85
Equity Repurchase (Common, Net)
— — — (1.15)
Dividends Paid (Total)
0.00 — 0.00 —
Other financial activities
(10.12) — (9.01) (3.84)
Financing cash flow
43.12 — 363.23 10.86
Exchange Rate Adjustment
1.88 — (9.04) (7.60)
Change in Cash
(19.86) — 43.28 54.73
Beginning Cash
142.21 — 127.71 176.24
Ending Cash
122.35 — 171.00 230.97
Dividends Paid (Common)
0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
15.20 — (20.52) —
Investments Change (Net)
(2.19) — (0.57) (0.44)
Issuance/Purchase of Shares
73.15 — 328.31 (1.15)

Fold the line items

In millions of $ except per-share values · columns are period end dates